Musing over the last interview
I have been musing over the short interview and wanted to share with you my thoughts:
First of all, why was this done in the first place? It was very short and unnecessary (maybe). Three things are possible IMO:
1) Wanted to share with us the progress of his mother.
2) Wanted us to see Dr. Bruce Patterson and support the price with his positive, implicit backing by means of his scientific comments
3) Wanted to tell us that something has changed with the deal (in which case Dr. Patterson appearance was simply a filler as otherwise the interview would had been very difficult to make as NP did not want to talk about anything else, details.
These “interviews” are of, course, highly staged and a means of him to communicate with us. In this particular case, was not even a pitch as did not say anything else about the company and was only addressing people “in the know” (us shareholders) and not posible stock buyers.
I think the most probable reason is the latter (something has changed). Reading “between lines” (all of this is simply my opinion, I do not have any more information than anybody else and have been wrong in the past) I think the deal is finalized but “something” came out as of late and now NP does not feel that signing it is the right thing to do.
This can be positive or negative.
Negative: If it means that the final agreement is not what he wanted and the partner does not want to move from its negotiating position. The deal is finished and can be signed as is but CYDY is not that happy with the final product.
Also, there is the possibility that the deal is over (partner or CYDY pulled off and NP want to “prepare us” for the bad news slowly.
The interview was simply a “buy time” mechanism where the deal will take much longer and he is simply telling us that it is there, but not going at the expected speed.
Positive if it means that something else has come up:
A possible offer in Oncoloy, however this does not explain why we can’t close the USA HIV deal and negotiate this independently.
A larger pharma (now not a middle pharma but a BP) is interested and CYDY wants to explore the possibility of, rather, negotiating with them.
An offer for another indication (NASH?) that would give CYDY the freedom to have prompt economic independence and pursue a better deal for HIV (or go solo).
A BO offer for the whole enchilada, no questions asked, no this yes and that no. To buy the CCR5 antagonist (patents) for whatever indication under the sun. Period. This would prevent NP from selling HIV rights and would kill the ongoing deal with the middle-pharma.
We will know soon. I hope it is a positive development, but ... difficult to place the truth without more info.
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Nucor's Solid Third Quarter Performance Nucor Corporation is flexing its muscles, reporting a robust third quarter for 2026. With net earnings hitting $1.32 billion and a diluted earnings per share of $5.80, the steel giant has shown it can more than hold its ground in a competitive market. Compare that to last quarter's $1.16 billion - we're seeing serious momentum....
Continue Reading
New Heights in Trackside Fashion Well, it looks like Pacsun's got a knack for making the Austin F1 scene as thrilling as the race itself, weaving fashion into the high-speed atmosphere. This year's Formula 1 United States Grand Prix in Austin brought a whopping 19% sales swell in 2026, marking a total sales increase of 177% since their initial 2023 Austin pop-up. Talk...
Continue Reading
Anticipation Builds for NACCO's Q3 Financial Insights From the streets of Cleveland, NACCO Industries is ramping up to release their third quarter financial results for 2026. Mark your calendars for November 4, just after the market packs up for the day. Now, isn't it something to watch how these earnings reports seem to become a spectacle all their own? Promising...
Continue Reading
Another Day, Another Lawsuit Just when you thought the financial waters were calm, there's a storm brewing for Bank of America Corp. (NYSE: BAC). They've been slapped with a securities class action lawsuit that screams all kinds of regulatory and compliance failures. You’d think with all that cash flow, BAC could afford to run a tight ship. But apparently, they decided...
Continue Reading
Ah, the holidays—they're creeping up like a kid sneaking downstairs for a peek at their gifts. But it's not the gifts under the tree that brighten a room, it's those lights draping the tree itself. Enter Govee, bringing us back to that vintage glow we all remember from our childhoods. They've teamed up with Brady Tolbert, a design whiz who can make a living room look...
Continue Reading
Insights from the SPS Report on AI and Workplace Data When data, AI, and human context play in harmony, businesses dance to a new tune. SPS has shed some light on this dynamic in their freshly minted report, "Turning Workplace Data into a Competitive Advantage." Now, anyone paying attention to the tech-driven evolution of business will see that merely piling up workplace...
Continue Reading
Breaking Down Sands China's Bond Maneuver Today, we found out that Sands China is teeing up a fresh round of senior unsecured notes. Now, if that doesn't get your ticker flickin', maybe you're too used to market snoozefests. The folks at the helm of Sands China, a subsidiary under the mighty Las Vegas Sands Corp. (NYSE: LVS), are rolling out these USD-denominated notes...
Continue Reading
Packed Protein, Zero Hassle Every once in a while, something comes along in the food sector that changes the game. Tempo's Protein Max meals might just be it. Launching with a hefty 40 grams of protein in every serving, these meals promise a powerful punch for anyone who's serious about meeting their protein counts without spending hours in the kitchen. Two minutes flat...
Continue Reading
A Melody and Brew-Infused South Florida Celebration Boy, if festivals were stocks, I'd have bought into the Beer B Que Music Festival years ago. This event, rolling into its seventh year, isn't just another line-up of artists—it feels like a genuine cultural reunion for folks in South Florida. You throw in some heavyweight names like Rick Ross and Kodak Black, plus the...
Continue Reading
Worldline's Journey to Leadership When you talk about the big dogs in payment services, Worldline’s name crops up for a reason. They've just snagged a top spot in the 2026 SPARK Matrix by the QKS Group, putting them in the limelight as a leader in Merchant Payment Platform technology. If you're in payments, this is worth a double take. The SPARK Matrix Breakdown The...
Continue Reading
Top 5 Most Recently Viewed Articles
Community Healthcare Trust Shows Strong Financial Performance Community Healthcare Trust Incorporated (NYSE: CHCT) has recently reported its financial results for the three-month period ending on December 31, 2024. The Company recorded a net income of approximately $1.8 million, which translates to about $0.04 per diluted common share. Furthermore, for the same period,...
Continue Reading
Celebrate Every Mini Win This Monday with DOVE Ice Cream Getting through Mondays can be a challenge, but DOVE® Ice Cream is transforming this weekly hurdle into a delightful celebration. Introducing the #MiniWinMonday initiative, this campaign is designed to acknowledge and celebrate those small victories that often get overlooked. Whether it's completing a task or...
Continue Reading
Wall Street witnessed quite the spectacle back then, as both the Nasdaq Composite and the S&P 500 hit record-breaking closes. This surge was fueled by investor optimism amid those ongoing Fed policy discussions and economic indicators that seemed to change every minute. Market Peaks: Numbers Never Lie? The Nasdaq Composite increased about 0.6%, while the S&P 500 saw an...
Continue Reading
4TEEN4 Pharmaceuticals Initiates Trial for Procizumab 4TEEN4 Pharmaceuticals GmbH has reached an important milestone with the initiation of the PROCARD1 clinical trial, focusing on their monoclonal antibody, procizumab. This trial represents a significant step in treating cardiogenic shock, a critical condition resulting from severe circulatory failure. Shock is a serious...
Continue Reading
NVIDIA's Introduction of Evo 2 for Advanced Genetic Research NVIDIA (NVDA) has unveiled an innovative artificial intelligence system called Evo 2, designed to enhance biological research capabilities. Transforming Genetics with AI Evo 2 rapidly analyzes and generates genetic code from varied organisms, significantly furthering advancements in genetics and medicine. NVIDIA...
Continue Reading